SCHEMBL16702192

SCHEMBL16702192

C=CS(=O)(=O)N(CCn1nc(-c2ccc(OCC)c(OC)c2)c2c(N)ncnc21)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 15/20 0.63
PRKDC P78527 15/20 0.63
EGFR P00533 14/20 0.63
PIK3CA P42336 14/20 0.63
PIK3CB P42338 14/20 0.63
PIK3CG P48736 14/20 0.63
ABL1 P00519 13/20 0.63
SRC P12931 13/20 0.63
HCK P08631 12/20 0.63
MTOR P42345 12/20 0.63
EPHB4 P54760 12/20 0.63
KDR P35968 11/20 0.63
PI4KB Q9UBF8 10/20 0.63
FGFR1 P11362 2/20 0.51
FGFR2 P21802 2/20 0.51
FGFR3 P22607 2/20 0.51
LCK P06239 2/20 0.48
JAK3 P52333 2/20 0.48
BTK Q06187 2/20 0.48
ITK Q08881 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16702052 0.95 PIK3CD (0.56) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701780 0.90 PIK3CD (0.59) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701700 0.90 PIK3CD (0.51) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701674 0.89 SRC (0.48) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16702036 0.85 EGFR (0.64) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701773 0.84 EGFR (0.49) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701652 0.83 EGFR (0.51) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701704 0.83 PIK3CD (0.53) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16701616 0.83 EGFR (0.50) PIK3CDPRKDCEGFRPIK3CAPIK3CB
SCHEMBL16702423 0.82 FGFR1 (0.55) PIK3CDEGFRFGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US claimed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO claimed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272645-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885PRKDC 34/4885EGFR 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.